INKT · MiNK Therapeutics, Inc. · Executive Compensation
$12.73
+0.18 (+1.43%)
At close · Oct 1
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because the completion of anticipated funding is not entirely within the Company's control, the Company is required to disclose that substantial doubt exists about its ability to continue as a going concern for a period of one year after the date of filing of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 13, 2026
Market Cap
$62.15M
Shares
5.10M
Volume · Oct 1
26.68K
Avg daily vol (3M)
13.03K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Jennifer Buell | President and Chief Executive Officer | $2,087,881 |
| Christine Klaskin | Consultant and Former Treasurer | $29,822 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Jennifer Buell | President and Chief Executive Officer | $798,686 |
| Marc Van Dijk | Strategic Consultant and Scientific Advisory Board Member; Former Chief Scientific Officer | $402,479 |
| Christine Klaskin | Treasurer | $29,822 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jennifer Buell | President and Chief Executive Officer | $2,807,439 |
| Marc Van Dijk | Strategic Consultant and Scientific Advisory Board Member; Former Chief Scientific Officer | $568,829 |
| Christine Klaskin | Treasurer | $29,624 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jennifer Buell | President and Chief Executive Officer | $3,871,880 |
| Marc Van Dijk | Chief Scientific Officer | $651,174 |
| Christine Klaskin | Treasurer | $27,244 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jennifer Buell | President and Chief Executive Officer | $3,890,774 |
| Patrick N. Jordan | Vice President of Business Operations | $515,156 |
| Marc Van Dijk | Chief Scientific Officer | $107,074 |
| Christine Klaskin | Treasurer | $20,019 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Patrick N. Jordan | Vice President of Business Operations | $154,700 |
| Jennifer Buell | President and Chief Executive Officer | $917 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Austin Charette | Principal Accounting Officer | Appointed | 2026-03-19 |
| Melissa Orilall | Principal Financial Officer | Appointed | 2026-03-19 |
| Robert Kadlec, MD | Board of Directors | Resigned | 2026-01-02 |
| John Holcomb | Class II director | Appointed | 2025-09-29 |
| Robert Kadlec | Class II director | Appointed | 2024-10-31 |
| Dr. Marc Van Dijk | Scientific Advisory Board Member and Strategic Consultant | Appointed | 2024-10-18 |
| Dr. John Baldoni | director | Resigned | 2023-10-17 |